PubMed Health⌕ Search

Biomedical subjects

L O Dolva

Publications and source records attributed to L O Dolva.

28 records · Page 2Linked to original sources

Biosynthesis and release of thyrotropin-releasing hormone immunoreactivity in rat pancreatic islets in organ culture. Effects of age, glucose, and streptozotocin.

Thyrotropin-releasing hormone immunoreactivity (TRH-IR) was measured in isolated islets and in medium from rat pancreatic islets maintained in organ culture. TRH-IR in methanol extracts of both islets and culture medium was eluted in the same position as synthetic TRH by ion-exchange and gel chromatography and exhibited dilution curves parallel with synthetic TRH in radioimmunoassay. [3H]Histidine was incorporated into a component that reacted with TRH antiserum and had the same retention time as synthetic TRH on reversed-phase high-performance liquid chromatography. A continuous release of TRH-IR into the culture medium was observed from islets of both 5-d-old (newborn) and 30-d-old (adult) rats with a maximum on the second day of culture (28.7 +/- 7.0 and 13.3 +/- 3.6 fmol/islet per d, respectively). The content of TRH-IR was higher in freshly isolated islets from newborn rats (22.4 +/- 2.3 fmol/islet) than in adult rat islets, which, however, increased their content from 1.3 +/- 0.5 to 7.0 +/- 0.5 fmol/islet during the first 3 d of culture. Adult rat islets maintained in medium with 20 mM glucose released significantly more TRH-IR than islets in 3.3 mM glucose medium (13.0 +/- 0.7 vs. 4.3 +/- 0.3 fmol/islet per d). In contrast, the content of TRH-IR in the islets was reversed (1.4 +/- 0.3 vs. 4.7 +/- 1.6 fmol/islet). By exposing islets from newborn rats to streptozotocin 0.7 mg/ml for 30 min, a 50% reduction of TRH-IR content in the islets compared with the non-treated islets was seen after subsequent culture for 7 d. The insulin content was reduced by 80%, while glucagon was slightly elevated. In conclusion, these results indicate that TRH is synthesized in rat pancreatic islets, and that the release is stimulated by glucose.

Aging↗

Thyrotropin-releasing hormone immunoreactivity in the gastrointestinal tract of man.

TRH inhibits gastric secretion, gastric motility, and pancreatic enzyme secretion in man. We measured TRH immunoreactivity (TRH-IR) in mucosal and transmural biopsies from different parts of the stomach, pylorus, duodenum, and pancreas in patients undergoing surgery or gastroscopy. TRH-IR was found in pancreas (range, 1.64-3.27 pg TRH/mg protein) and in mucosa of the fundus (13.3 +/- 2.0 pg TRH/mg protein), antrum (22.5 +/- 4.5 pg TRH/mg protein), and duodenum (35.5 +/- 6.4 mg TRH/mg protein). Low levels of TRH-IR were found in transmural biopsies from fundus, antrum, and pylorus (range, 0.45-0.87 pg TRH/mg protein). Chromatography of gastrointestinal tissue extracts on a cation exchange column resulted in two different TRH-IR peaks, one eluted at pH 3.5 and the other eluted at pH 7.4. The peak at pH 7.4 corresponded to synthetic TRH. The presence and the action of TRH in human gut indicate a physiological role of TRH in the gastrointestinal tract in man.

Animals↗

The effect of thyrotrophin-releasing hormone (TRH) on pancreatic hormone secretion in normal subjects.

Thyrotrophin-releasing hormone (TRH) is present in the pancreas, mainly in the islets of Langerhans. We studied the effect of iv infused TRH on the plasma levels of pancreatic islet hormones in man, under different experimental conditions: 1) Arginine infusion. 2) Insulin induced hypoglycaemia. 3) Glucose clamp technique (maintainance of normoglycaemia by glucose infusion during insulin infusion). 4) TRH injection. Except for a minor inhibition of glucagon and pancreatic polypeptide following hypoglycaemic stimulation in one study, TRH had no significant effect on basal, stimulated or inhibited plasma glucagon, on insulin, somatostatin, pancreatic polypeptide or blood glucose. It is concluded that iv administration of TRH does not produce significant changes in peripheral plasma levels of pancreatic hormones. Application of techniques, which allow studies closer to the pancreatic islet, is probably necessary to assess the role of TRH in the regulation of endocrine pancreas.

Adult↗

Effect of thyrotropin-releasing hormone and atropine on the gastric motility stimulated by insulin-induced hypoglycemia.

The effects of thyrotropin-releasing hormone (TRH) and atropine on the gastric motility after stimulation by insulin-induced hypoglycemia were studied by the intragastric balloon technique. Four healthy young men were examined in two different ways on different days. In one experiment the effect of 50 micrograms TRH, 500 micrograms atropine, and 10 micrograms TRH, all intravenously injected, and in the other 500 micrograms atropine and 50 micrograms TRH were analyzed in this specific sequence. In two subjects the effect of intravenously injected TRH, 200 micrograms, and atropine, 500 micrograms, on the carbacholine-stimulated gastric motility was tested. The hypoglycemic stimulation of the gastric motility was immediately and completely blocked for a period of 9.3 +/- 0.7 min after 50 micrograms TRH and for 3.4 +/- 0.1 min after 10 micrograms TRH. The intragastric basal pressure was immediately reduced in all after TRH injection (-2.5 +/- 0.48 cm H2O pressure). Atropine had no significant effect on the gastric motility after hypoglycemic stimulation. The inhibiting effect of TRH on the carbacholine-stimulated gastric motility was similar to the effect of TRH on the hypoglycemia-stimulated gastric motility. These results demonstrate that TRH effectively inhibits the atropine-resistant stimulation of the gastric motility after insulin-induced hypoglycemia and also has potent relaxing effects on the muscular tonus of the gastric wall.

Adult↗

Effect of thyrotropin-releasing hormone on gastric acid secretion in man.

Thyrotropin-releasing hormone (TRH) has been shown to have a dose-dependent inhibiting effect on the pentagastrin-stimulated gastric acid secretion in man. We studied the effect of increasing doses of TRH on the gastric acid secretion stimulated by a submaximal histamine dose. The effect of a relatively high dose of TRH (500 micrograms/h) on the maximal histamine-stimulated acid secretion was examined. Furthermore, we studied the effect of two doses of TRH (40 micrograms/h and 500 micrograms/h) on the gastric acid output after insulin-induced hypoglycemia. A significant reduction of the submaximal histamine-stimulated gastric acid output was observed during infusion of 8 micrograms/h TRH (16%), 40 micrograms/h TRH (38%), and 200 micrograms/h TRH (42%) (percentage reduction compared with the control experiment). TRH, 1000 micrograms/h, had no significant effect. With regard to the acid output after maximal histamine stimulation, TRH 500 micrograms/h was without significant effect. After hypoglycemia the acid output was reduced by 30% during 40 micrograms/h TRH (p less than 0.05) and by 37% during 500 micrograms/h TRH (p less than 0.02). TRH had no effect on the acid concentration in any of the studies. The possible mechanisms by which TRH may interact with the acid regulation are discussed.

Adult↗

Thyrotrophin-releasing hormone inhibits the pentagastrin stimulated gastric secretion in man. A dose response study.

Actions of thyrotrophin-releasing hormone (TRH) have generally been confined to the central nervous system (CNS). We have studied the effect of increasing doses of TRH i.v. (8, 40, 200 and 1000 microgram/h) on pentagastrin-stimulated gastric secretion in ten normal individuals. All doses caused stepwise inhibition of gastric juice (volume), acid and pepsin output. When employing the largest dose of i.v. TRH (1000 microgram/h) the inhibition was 44% for gastric volume, 51% for acid output and 57% for pepsin output. This study shows that TRH inhibits gastric secretion, and indicates that TRH has actions outside the CNS in man.

Adult↗

Actions of thyrotropin-releasing hormone on the gastrointestinal function in man. II. Inhibition of pentagastrin-stimulated acid secretion.

The pentagastrin-stimulated gastric volume and acid output were measured with and without an i.v. thyrotropin-releasing hormone (TRH) infusion (666 microgram/h). TRH inhibited the pentagastrin (6 microgram/kg s.c.) stimulated volume to 67.5 +/- 8.4% (p less than 0.01) and the acid output to 65 +/- 8.4% of control infusion values (mean +/- S.E.M.). It is concluded that TRH inhibits the pentagastrin-stimulated gastric secretion in man.

Adult↗

Actions of thyrotropin-releasing hormone on gastrointestinal functions in man. III. Inhibition of gastric motility in response to distension.

The intragastric pressure/volume relationship has been measured in six healthy volunteers. Increased gastric motility was achieved by gastric distension, by stepwise increasing the volume from 0--600 ml. When thyrotropin-releasing hormone (TRH), 0.04 mg/h, was infused concomitantly in the individuals, gastric motility was significantly inhibited (p less than 0.05) and, with 1 mh/h of TRH, nearly abolished compared with the saline control test. The basal pressure was unaffected at 0.04 mg/h, whereas a significant rise was seen after 1 mg/h of TRH (p less than 0.05) compared with the control test. In three of the subjects the effect of rapid injection of TRH (0.2 mg), followed by infusion of TRH (0.6 mg/h), on the stimulated gastric motility was analysed. After the injection of TRH, almost no motor activity was observed during the 15-min observation period. It is concluded that TRH has a potent inhibiting effect on gastric motility, and the possible physiological role of TRH in the gastric regulation in man is discussed.

Adult↗